Literature DB >> 3183424

Rapid rebound of serum human immunodeficiency virus antigen after discontinuing zidovudine therapy.

J B Spear, C A Benson, J C Pottage, D A Paul, A L Landay, H A Kessler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3183424     DOI： 10.1093/infdis/158.5.1132

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  8 in total

Review 1.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

2.  Stabilities of free and complexed human immunodeficiency virus p24 antigens during short- and long-term storage.

Authors:  M Arens; W Meyer; D Brambilla; J Bremer; S Fiscus; B Griffith; S Hammer; R Hodinka; W Kabat; B Yen-Lieberman; L Myers; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

Review 3.  Zidovudine (Retrovir) update.

Authors:  A R Rachlis
Journal:  CMAJ       Date:  1990-12-01       Impact factor: 8.262

Review 4.  Zidovudine toxicity. Clinical features and management.

Authors:  A Rachlis; M M Fanning
Journal:  Drug Saf       Date:  1993-04       Impact factor: 5.606

Review 5.  Antiviral therapy in human immunodeficiency virus infection.

Authors:  E Sandström
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

6.  Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection.

Authors:  C Flexner; P A Barditch-Crovo; D M Kornhauser; H Farzadegan; L J Nerhood; R E Chaisson; K M Bell; K J Lorentsen; C W Hendrix; B G Petty
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

7.  How to prevent viremia rebound? Evidence from a PRRSv data-supported model of immune response.

Authors:  Natacha Go; Suzanne Touzeau; Zeenath Islam; Catherine Belloc; Andrea Doeschl-Wilson
Journal:  BMC Syst Biol       Date:  2019-01-29

8.  Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.

Authors:  Deepti Saxena; Michael Spino; Fernando Tricta; John Connelly; Bernadette M Cracchiolo; Axel-Rainer Hanauske; Darlene D'Alliessi Gandolfi; Michael B Mathews; Jonathan Karn; Bart Holland; Myung Hee Park; Tsafi Pe'ery; Paul E Palumbo; Hartmut M Hanauske-Abel
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.